Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
26433 | 255 | 33.3 | 65% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
12 | 4 | POLYMER SCIENCE//MATERIALS SCIENCE, PAPER & WOOD//CHEMISTRY, PHYSICAL | 1084170 |
41 | 3 | INTERNATIONAL JOURNAL OF PHARMACEUTICS//DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY//PHARMACOLOGY & PHARMACY | 99449 |
147 | 2 | SOLID LIPID NANOPARTICLES//POLYMERIC MICELLES//LIPOSOMES | 23275 |
26433 | 1 | 6 MALEIMIDOCAPROYLHYDRAZONE DERIVATIVE OF DOXORUBICIN//METHOTREXATE ALBUMIN//256 CARCINOSARCOMA WALKER | 255 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | 6 MALEIMIDOCAPROYLHYDRAZONE DERIVATIVE OF DOXORUBICIN | authKW | 359239 | 1% | 100% | 3 |
2 | METHOTREXATE ALBUMIN | authKW | 359239 | 1% | 100% | 3 |
3 | 256 CARCINOSARCOMA WALKER | authKW | 239493 | 1% | 100% | 2 |
4 | ALBUMIN BINDING PRODRUG | authKW | 239493 | 1% | 100% | 2 |
5 | CONJUGATE FRAGMENTS | authKW | 239493 | 1% | 100% | 2 |
6 | GELATIN METHOTREXATE CONJUGATES | authKW | 239493 | 1% | 100% | 2 |
7 | HL 60 GROWTH INHIBITION | authKW | 239493 | 1% | 100% | 2 |
8 | HYDROLYTIC RELEASE FROM PROTEIN CONJUGATES | authKW | 239493 | 1% | 100% | 2 |
9 | OVARIAN 342 TUMOR | authKW | 239493 | 1% | 100% | 2 |
10 | PROTEIN CONJUGATE STABILITY | authKW | 239493 | 1% | 100% | 2 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 885 | 31% | 0% | 80 |
2 | Pharmacology & Pharmacy | 557 | 29% | 0% | 73 |
3 | Chemistry, Medicinal | 417 | 13% | 0% | 32 |
4 | Chemistry, Organic | 55 | 8% | 0% | 21 |
5 | Chemistry, Multidisciplinary | 28 | 10% | 0% | 25 |
6 | Medicine, Research & Experimental | 23 | 5% | 0% | 12 |
7 | Materials Science, Biomaterials | 16 | 2% | 0% | 4 |
8 | Biochemical Research Methods | 15 | 4% | 0% | 9 |
9 | Biochemistry & Molecular Biology | 14 | 11% | 0% | 28 |
10 | Rheumatology | 12 | 2% | 0% | 4 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | RADIOCHEM RADIOPHARMACOL E0300 | 239493 | 1% | 100% | 2 |
2 | EXPT ANTICANC THER Y | 179617 | 1% | 50% | 3 |
3 | ASSOC MED ONCOL | 119746 | 0% | 100% | 1 |
4 | EXPT ANICANC THER Y | 119746 | 0% | 100% | 1 |
5 | FUJISAWA GRP | 119746 | 0% | 100% | 1 |
6 | KOPFKLINIKUM HEIDELBERG | 119746 | 0% | 100% | 1 |
7 | KOPFZENTRUM | 119746 | 0% | 100% | 1 |
8 | MEDAC GMBH | 119746 | 0% | 100% | 1 |
9 | NEOLEK | 119746 | 0% | 100% | 1 |
10 | PHASE STUDY GRP 1 | 119746 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | NEOPLASMA | 6521 | 5% | 0% | 13 |
2 | SBORNIK LEKARSKY | 3518 | 1% | 1% | 2 |
3 | FUNKTIONELLE BIOLOGIE & MEDIZIN | 1195 | 0% | 1% | 1 |
4 | BIOCONJUGATE CHEMISTRY | 1168 | 3% | 0% | 7 |
5 | ANTI-CANCER DRUGS | 910 | 2% | 0% | 5 |
6 | DRUG DELIVERY | 826 | 1% | 0% | 3 |
7 | THERANOSTICS | 813 | 1% | 0% | 2 |
8 | ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS | 719 | 1% | 0% | 3 |
9 | GANN | 638 | 1% | 0% | 2 |
10 | AMERICAN JOURNAL OF CANCER RESEARCH | 604 | 1% | 0% | 2 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | KREMER, P , HARTUNG, G , BAUDER-WUST, U , SCHRENK, HH , WUNDER, A , HECKL, S , ZILLMANN, U , SINN, H , (2002) EFFICACY AND TOLERABILITY OF AN AMINOPTERIN-ALBUMIN CONJUGATE IN TUMOR-BEARING RATS.ANTI-CANCER DRUGS. VOL. 13. ISSUE 6. P. 615 -623 | 17 | 74% | 10 |
2 | NEUMANN, E , FREI, E , FUNK, D , BECKER, MD , SCHRENK, HH , MULLER-LADNER, U , FIEHN, C , (2010) NATIVE ALBUMIN FOR TARGETED DRUG DELIVERY.EXPERT OPINION ON DRUG DELIVERY. VOL. 7. ISSUE 8. P. 915-925 | 19 | 43% | 45 |
3 | WUNDER, A , STEHLE, G , SCHRENK, HH , HARTUNG, G , HEENE, DL , MAIER-BORST, W , SINN, H , (1998) ANTITUMOR ACTIVITY OF METHOTREXATE-ALBUMIN CONJUGATES IN RATS BEARING A WALKER-256 CARCINOMA.INTERNATIONAL JOURNAL OF CANCER. VOL. 76. ISSUE 6. P. 884-890 | 15 | 79% | 18 |
4 | WARNECKE, A , FICHTNER, I , SASS, G , KRATZ, F , (2007) SYNTHESIS, CLEAVAGE PROFILE, AND ANTITUMOR EFFICACY OF AN ALBUMIN-BINDING PRODRUG OF METHOTREXATE THAT IS CLEAVED BY PLASMIN AND CATHEPSIN B.ARCHIV DER PHARMAZIE. VOL. 340. ISSUE 8. P. 389 -395 | 16 | 53% | 25 |
5 | GOU, Y , YANG, F , LIANG, H , (2016) DESIGNING PRODRUGS BASED ON SPECIAL RESIDUES OF HUMAN SERUM ALBUMIN.CURRENT TOPICS IN MEDICINAL CHEMISTRY. VOL. 16. ISSUE 9. P. 996 -1008 | 30 | 22% | 1 |
6 | WOLFF, D , FREI, E , HOFMEISTER, N , STEINER, B , KLEINE, HD , JUNGHANSS, C , SIEVERT, K , TERPE, H , SCHRENK, HH , FREUND, M , ET AL (2006) METHOTREXATE-ALBUMIN AND AMINOPTERIN-ALBUMIN EFFECTIVELY PREVENT EXPERIMENTAL ACUTE GRAFT-VERSUS-HOST DISEASE.TRANSPLANTATION. VOL. 82. ISSUE 4. P. 527 -533 | 15 | 60% | 6 |
7 | JAGIELLO, M , KANSKA, U , NEVOZHAY, D , BORATYNSKI, J , (2010) SYNTHESIS AND BIOLOGICAL ACTIVITY OF RALTITREXED-CARRIER CONJUGATES.ACTA BIOCHIMICA POLONICA. VOL. 57. ISSUE 1. P. 83-87 | 13 | 62% | 0 |
8 | GRAESER, R , ESSER, N , UNGER, H , FICHTNER, I , ZHU, A , UNGER, C , KRATZ, F , (2010) INNO-206, THE (6-MALEIMIDOCAPROYL HYDRAZONE DERIVATIVE OF DOXORUBICIN), SHOWS SUPERIOR ANTITUMOR EFFICACY COMPARED TO DOXORUBICIN IN DIFFERENT TUMOR XENOGRAFT MODELS AND IN AN ORTHOTOPIC PANCREAS CARCINOMA MODEL.INVESTIGATIONAL NEW DRUGS. VOL. 28. ISSUE 1. P. 14 -19 | 12 | 60% | 34 |
9 | ELSADEK, B , GRAESER, R , ESSER, N , SCHAFER-OBODOZIE, C , ABU AJAJ, K , UNGER, C , WARNECKE, A , SALEEM, T , EL-MELEGY, N , MADKOR, H , ET AL (2010) DEVELOPMENT OF A NOVEL PRODRUG OF PACLITAXEL THAT IS CLEAVED BY PROSTATE-SPECIFIC ANTIGEN: AN IN VITRO AND IN VIVO EVALUATION STUDY.EUROPEAN JOURNAL OF CANCER. VOL. 46. ISSUE 18. P. 3434-3444 | 14 | 52% | 20 |
10 | BURGER, AM , HARTUNG, G , STEHLE, G , SINN, H , FIEBIG, HH , (2001) PRE-CLINICAL EVALUATION OF A METHOTREXATE-ALBUMIN CONJUGATE (MTX-HSA) IN HUMAN TUMOR XENOGRAFTS IN VIVO.INTERNATIONAL JOURNAL OF CANCER. VOL. 92. ISSUE 5. P. 718-724 | 14 | 61% | 31 |
Classes with closest relation at Level 1 |